Live Epidemiological Tracking of COVID-19 in Senegalese Participants of the Hajj

Year : 2025 | Volume : 02 | 02 | Page : –
    By

    Dr. Aminata Mboup,

  • Abdou Padane,

  • Dr. Yacine Amet Dia,

  • Mr. Seyni Ndiaye,

  • Dr. Marièma Sarr,

  • M. Marilyne Aza-Gnandji,

  • Mr. Mamadou Ndao,

  • Mr. Abdoulaye Samba Diallo,

  • Mr. Ousmane Diop,

  • Mr. Bacary Dembo Diatta,

  • Mr. Ousmane Diouf,

  • Mr. Abdoulaye Leye Sarr,

  • M. Ndèye Astou Dabo,

  • M. Seynabou Selbé Diouf,

  • M. Aissatou Nogaye Dieng,

  • Mr. Mame Matar Diop,

  • Mr. Abdoulaye Souaré,

  • M. Ndèye Dieynaba Diouf,

  • Dr. Nafissatou Leye,

  • Dr. Astou Gueye,

  • Dr. Aminata Dia,

  • Dr. Mame Sokhna Gueye,

  • Djibril Wade,

  • Cyrille Kouligueul Diédhiou,

  • Ambroise Ahouidi,

  • Papa Alassane Diaw,

  • Badara Cissé,

  • Moustapha Mbow,

  • Boly Diop,

  • Raghavendra G. Amachawadi,

  1. Head of Data Management Platform, The Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Dakar, Senegal
  2. Head of Genomic Platform and BSL3 Laboratory, The Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Dakar, Senegal
  3. Microbiologist and Medical Biologist, The Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Dakar, Senegal
  4. Researcher Microbiologist, The Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Dakar, Senegal
  5. Microbiologist, The Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Dakar, Senegal
  6. Head of Bioinformatic Unit, The Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Dakar, Senegal
  7. Bioinformatician, The Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Dakar, Senegal
  8. Data Scientist, The Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Dakar, Senegal
  9. Data Scientist, The Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Dakar, Senegal
  10. Data Scientist,, The Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Dakar, Senegal
  11. Statistician, The Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Dakar, Senegal
  12. Biologist, The Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Dakar, Senegal
  13. Biologist, The Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Dakar, Senegal
  14. Biologist, The Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Dakar, Senegal
  15. Biologist, The Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Dakar, Senegal
  16. Biologist, The Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Dakar, Senegal
  17. Biologist, The Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Dakar, Senegal
  18. Technician, The Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Dakar, Senegal
  19. Biologist, The Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Dakar, Senegal
  20. Head of Virology Platform, The Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Dakar, Senegal
  21. Medical Biologist, The Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Dakar, Senegal
  22. Microbiologist and Medical Biologist, The Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Dakar, Senegal
  23. Biologist, The Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Dakar, Senegal
  24. Biologist, The Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Dakar, Senegal
  25. Biologist, The Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Dakar, Senegal
  26. Medical Biologist, The Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Dakar, Senegal
  27. Medical Epidemiologist, The Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Dakar, Senegal
  28. Professor, The Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Dakar, Senegal
  29. Medical Epidemiologist, Department of Prey of vention of MinistrHealth Fann Résidence, Rue Aimé Césaire, Dakar, Senegal
  30. Associate Professor, Department of Clinical Sciences, College of Veterinary Medicine, Kansas State University,, kansas, USA

Abstract

Background: Since the COVID-19 outbreak, global efforts have focused on controlling the disease. However, intense cross border movements pose a risk for the emergence of new SARS-CoV-2 strains. A recent example is the detection of cases among the 2024 Senegalese pilgrims returning from Mecca, Saudi Arabia. Investigations of these cases have revealed genomic evolution of the virus. The lack of surveillance may lead to the emergence of high-threat strains. This study aims to identify new SARS-CoV-2 emerging lineages isolated from returning Senegalese Pilgrims.Methods: Whole Genome Sequencing, using midnight protocol on ONT platform, has been used to characterize SARS-CoV-2 strains isolated from pilgrims. An integrated approach, involving strong collaboration with the Ministry of Health (MoH), was utilized for data sharing with patients and healthcare authorities.Results: Among 66 positive samples sequenced with coverage ≥ 80%, we detected the presence of the JN.1 sub-lineage (47.5%) and the emergence of the JN.1.18 variant (3.27%). In addition, JN.1.18.3 (21.311%) had many mutations more than JN.1. The other variants, LF.1.1.1 (6.56%), JN.1.16 (1.56%), JN.1.18.2 (1.64%), KP.1.1.1 (4.91%), KP.1.1.3 (3.27%), LP.2 (3.27%). LB.1.4 (4.91%), and KS.1.1 (1.645%) have never been identified in Africa. New lineages LS.1 (2.54%) and JN.1.18.5 (3.27%) were identified in real time during this intervention.Conclusion: It is important to monitor the emergence of new variants among pilgrims and the general population, as well as the clinical course of patients, to determine the virulence of these variants.

Keywords: COVID-19, SARS-CoV-2, Pilgrims, New lineages, Genomic Surveillance, Senegal.

How to cite this article:
Dr. Aminata Mboup, Abdou Padane, Dr. Yacine Amet Dia, Mr. Seyni Ndiaye, Dr. Marièma Sarr, M. Marilyne Aza-Gnandji, Mr. Mamadou Ndao, Mr. Abdoulaye Samba Diallo, Mr. Ousmane Diop, Mr. Bacary Dembo Diatta, Mr. Ousmane Diouf, Mr. Abdoulaye Leye Sarr, M. Ndèye Astou Dabo, M. Seynabou Selbé Diouf, M. Aissatou Nogaye Dieng, Mr. Mame Matar Diop, Mr. Abdoulaye Souaré, M. Ndèye Dieynaba Diouf, Dr. Nafissatou Leye, Dr. Astou Gueye, Dr. Aminata Dia, Dr. Mame Sokhna Gueye, Djibril Wade, Cyrille Kouligueul Diédhiou, Ambroise Ahouidi, Papa Alassane Diaw, Badara Cissé, Moustapha Mbow, Boly Diop, Raghavendra G. Amachawadi. Live Epidemiological Tracking of COVID-19 in Senegalese Participants of the Hajj. Recent Trends in Infectious Diseases. 2025; 02(02):-.
How to cite this URL:
Dr. Aminata Mboup, Abdou Padane, Dr. Yacine Amet Dia, Mr. Seyni Ndiaye, Dr. Marièma Sarr, M. Marilyne Aza-Gnandji, Mr. Mamadou Ndao, Mr. Abdoulaye Samba Diallo, Mr. Ousmane Diop, Mr. Bacary Dembo Diatta, Mr. Ousmane Diouf, Mr. Abdoulaye Leye Sarr, M. Ndèye Astou Dabo, M. Seynabou Selbé Diouf, M. Aissatou Nogaye Dieng, Mr. Mame Matar Diop, Mr. Abdoulaye Souaré, M. Ndèye Dieynaba Diouf, Dr. Nafissatou Leye, Dr. Astou Gueye, Dr. Aminata Dia, Dr. Mame Sokhna Gueye, Djibril Wade, Cyrille Kouligueul Diédhiou, Ambroise Ahouidi, Papa Alassane Diaw, Badara Cissé, Moustapha Mbow, Boly Diop, Raghavendra G. Amachawadi. Live Epidemiological Tracking of COVID-19 in Senegalese Participants of the Hajj. Recent Trends in Infectious Diseases. 2025; 02(02):-. Available from: https://journals.stmjournals.com/rtid/article=2025/view=215833


References

  1. Al-Tawfiq JA, Kattan RF, Memish ZA. Escalating the 2022 Hajj during the third year of the COVID-19 pandemic. J Travel Med. 2022 Aug 1;29(6):taac059.
  2. Memish ZA, Steffen R, White P, Dar O, Azhar EI, Sharma A, et al. Mass gatherings medicine: public health issues arising from mass gathering religious and sporting events. Lancet. 2019 May 18;393(10185):2073‑84.
  3. General Authority for Statistics. GASTAT: Total number of pilgrims in 1445 H Hajj season is 1,833,164. 2024 [cited 2024 Jul 24]. Available from: https://www.stats.gov.sa/en/news/532
  4. Gueye K, Padane A, Diédhiou CK, Ndiour S, Diagne ND, Mboup A, et al. Evolution of SARS-CoV-2 strains in Senegal: From a wild Wuhan strain to the Omicron variant. COVID. 2022 Aug;2(8):1116‑24.
  5. Padane A, Diedhiou CK, Gueye K, Ndiour S, Diagne ND, Mboup A, et al. Dynamics of variants of concern (VOC) of SARS-CoV-2 during the different waves of COVID-19 in Senegal. COVID. 2022 Jun;2(6):691‑702.
  6. Selvavinayagam ST, Sankar S, Yong YK, Murugesan A, Suvaithenamudhan S, Hemashree K, et al. Emergence of SARS-CoV-2 Omicron Variant JN.1 in Tamil Nadu, India – Clinical Characteristics and Novel Mutations. medRxiv [Preprint]. 2024 Apr 19;2024.04.16.24305882.
  7. Looi MK. Covid-19: WHO adds JN.1 as new variant of interest. BMJ. 2023 Dec 21;383:2975.
  8. Aza-Gnandji M, Padane A, Ndiaye S, Sarr M, Diedhiou C, Gueye A, et al. Real time characterization of BA.2.86 and its variant (JN.1) in Senegal using Midnight protocol. Int J Vaccines. 2024 Jul 1.
  9. Padane A, Wade D, Diedhiou CK, Sarr M, Ndiaye S, Souaré A, et al. Specific mutations identified in patients vaccinated and infected with COVID-19 in Senegal. Med Res Arch. 2024 Mar 1 [cited 2024 Jul 24];12(2). Available from: https://esmed.org/MRA/mra/article/view/4956
  10. COM. Premier journal en ligne au Sénégal et en Afrique de l’ouest. [cited 2024 Aug 2]. Available from: https://www.pressafrik.com
  11. Health Minister announces success of health plans for Hajj 202. [cited 2024 Jul 24]. Available from: https://spa.gov.sa/
  12. Kandeel A, Fahim M, Deghedy O, BahaaEldin H, Roshdy WH, Khalifa MK, et al. Comparative analysis of COVID-19 and influenza prevalence among Egyptian pilgrims returning from Hajj and Umrah in 2022: epidemiology, clinical characteristics, and genomic sequencing. Arch Public Health. 2024 Jan 12;82(1):6.
  13. Assiri AM, Alsuraihi H, Alshahrani AMM, Alzaid SZ, Albarraq AM, Asiri S, et al. Viral aetiology of severe acute respiratory illness among patients admitted during the 2022 peri-Hajj period. IJID Reg. 2023 Sep 1;8:28‑30.
  14. National Heart, Lung, and Blood Institute. Study quality assessment tools. [cited 2024 Jul 24]. Available from: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools
Ahead of Print Subscription Original Research
Volume 02
02
Received 01/03/2025
Accepted 26/06/2025
Published 30/06/2025
Publication Time 121 Days
Total Visits: 27


My IP

PlumX Metrics